{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:15:56Z","timestamp":1784632556288,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T00:00:00Z","timestamp":1485820800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"crossref","award":["NO.2016A020217013"],"award-info":[{"award-number":["NO.2016A020217013"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"crossref","award":["GD-HK Cooperative Project NO.2016A050503030"],"award-info":[{"award-number":["GD-HK Cooperative Project NO.2016A050503030"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Planning Project of Guangzhou","award":["Key Laboratory Project NO.151800010"],"award-info":[{"award-number":["Key Laboratory Project NO.151800010"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Neurosci"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s12031-017-0891-3","type":"journal-article","created":{"date-parts":[[2017,1,31]],"date-time":"2017-01-31T06:41:25Z","timestamp":1485844885000},"page":"498-510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson\u2019s Disease Model"],"prefix":"10.1007","volume":"61","author":[{"given":"Zheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizuo","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenshen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yewei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,31]]},"reference":[{"key":"891_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1743-0003-2-20","volume":"2","author":"I Amende","year":"2005","unstructured":"Amende I, Kale A, McCue S, Glazier S, Morgan JP, Hampton TG (2005) Gait dynamics in mouse models of Parkinson\u02bcs disease and Huntington\u02bcs disease. J Neuroeng Rehabil 2:20. doi: 10.1186\/1743-0003-2-20","journal-title":"J Neuroeng Rehabil"},{"key":"891_CR2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.neuroscience.2011.11.036","volume":"202","author":"XQ Bao","year":"2012","unstructured":"Bao XQ, Kong XC, Qian C, Zhang D (2012) FLZ protects dopaminergic neuron through activating protein kinase B\/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson\u02bcs disease models. Neuroscience 202:396\u2013404","journal-title":"Neuroscience"},{"key":"891_CR3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1089\/ars.2008.2242","volume":"11","author":"MJ Calkins","year":"2009","unstructured":"Calkins MJ, Johnson DA, Townsend JA, Vargas MR, Dowell JA, Williamson TP, Kraft AD, Lee JM, Li J, Johnson JA (2009) The Nrf2\/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Sign 11:497\u2013508","journal-title":"Antioxid Redox Sign"},{"key":"891_CR4","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrc883","volume":"2","author":"S Cory","year":"2002","unstructured":"Cory S, Adams JM (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2:647\u2013656","journal-title":"Nat Rev Cancer"},{"key":"891_CR5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/cns.12203","volume":"20","author":"W Cui","year":"2014","unstructured":"Cui W, Zhang ZJ, Hu SQ, Mak SH, Xu DP, Choi CL, Wang YQ, Tsim WK, Lee MY, Rong JH, Han YF (2014) Sunitinib produces neuroprotective effect via inhibiting nitric oxide overproduction. CNS Neurosci Ther 20:244\u2013252","journal-title":"CNS Neurosci Ther"},{"key":"891_CR6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","volume":"7","author":"GL Ellman","year":"1961","unstructured":"Ellman GL, Courtney KD, Andres V, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88\u201395","journal-title":"Biochem Pharmacol"},{"key":"891_CR7","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","volume":"351","author":"M Emre","year":"2004","unstructured":"Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A (2004) Rivastigmine for dementia associated with Parkinson\u02bcs disease. N Engl J Med 351:2509\u20132518","journal-title":"N Engl J Med"},{"key":"891_CR8","first-page":"1.13.1","volume-title":"Current protocols in neuroscience","author":"DI Finkelstein","year":"2004","unstructured":"Finkelstein DI, Stanic D, Parish CL, Drago J, Horne MK (2004) Quantified assessment of terminal density and innervation. In: Charles RG, Andrew H, David S, Phil S, Susan W (eds) Current protocols in neuroscience, 2nd edn. John Wiley and Sons, New York, pp 1.13.1\u20131.13.16","edition":"2nd"},{"key":"891_CR9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.freeradbiomed.2013.01.033","volume":"62","author":"RA Floyd","year":"2013","unstructured":"Floyd RA, Castro Faria Neto HC, Zimmerman GA, Hensley K, Towner RA (2013) Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines. Free Radic Biol Med 62:145\u2013156","journal-title":"Free Radic Biol Med"},{"key":"891_CR10","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.freeradbiomed.2008.08.017","volume":"45","author":"RA Floyd","year":"2008","unstructured":"Floyd RA, Kopke RD, Choi CH, Foster SB, Doblas S, Towner RA (2008) Nitrones as therapeutics. Free Radic Biol Med 45:1361\u20131374","journal-title":"Free Radic Biol Med"},{"key":"891_CR11","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8501693","author":"J Folch","year":"2016","unstructured":"Folch J, Petrov D, Ettcheto M, Abad S, S\u00e1nchez-L\u00f3pez E, Garc\u00eda ML, Olloquequi J, Beas-Zarate C, Auladell C, Camins A (2016) Current research therapeutic strategies for Alzheimer\u2019s disease treatment. Neural Plast. doi: 10.1155\/2016\/8501693","journal-title":"Neural Plast"},{"key":"891_CR12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.neuroscience.2013.01.007","volume":"236","author":"HL Gao","year":"2013","unstructured":"Gao HL, Li C, Nabeka H, Shimokawa T, Saito S, Wang ZY, Cao YM, Matsuda S (2013) Attenuation of MPTP\/MPP+ toxicity in vivo and in vitro by an 18-mer peptide derived from prosaposin. Neuroscience 236:373\u2013393","journal-title":"Neuroscience"},{"key":"891_CR13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1124\/jpet.115.230201","volume":"356","author":"DS Goldstein","year":"2016","unstructured":"Goldstein DS, Jinsmaa Y, Sullivan P, Holmes C, Kopin IJ, Sharabi Y (2016) Comparison of monoamine oxidase inhibitors in decreasing production of the autotoxic dopamine metabolite 3, 4-dihydroxyphenylacetaldehyde in PC12 cells. J Pharmacol Exp Ther 356:484\u2013493","journal-title":"J Pharmacol Exp Ther"},{"key":"891_CR14","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1073\/pnas.040556597","volume":"97","author":"A Hartmann","year":"2000","unstructured":"Hartmann A, Hunot S, Michel PP, Muriel MP, Vyas S, Faucheux BA, Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, Hirsch EC (2000) Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson\u02bcs disease. Proc Natl Acad Sci U S A 97:2875\u20132880","journal-title":"Proc Natl Acad Sci U S A"},{"key":"891_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10943","author":"K Hasegawa","year":"2016","unstructured":"Hasegawa K, Yasuda T, Shiraishi C, Fujiwara K, Przedborski S, Mochizuki H, Yoshikawa K (2016) Promotion of mitochondrial biogenesis by necdin protects neurons against mitochondrial insults. Nat Commun. doi: 10.1038\/ncomms10943","journal-title":"Nat Commun"},{"key":"891_CR16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1474-4422(15)00389-0","volume":"15","author":"EJ Henderson","year":"2016","unstructured":"Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JC, Whone A, Ben-Shlomo Y (2016) Rivastigmine for gait stability in patients with Parkinson\u02bcs disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15:249\u2013258","journal-title":"Lancet Neurol"},{"key":"891_CR17","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/j.1471-4159.2006.04430.x","volume":"101","author":"P Huot","year":"2007","unstructured":"Huot P, Parent A (2007) Dopaminergic neurons intrinsic to the striatum. J Neurochem 101:1441\u20131447","journal-title":"J Neurochem"},{"key":"891_CR18","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.taap.2009.09.009","volume":"242","author":"YP Hwang","year":"2010","unstructured":"Hwang YP, Jeong HG (2010) Ginsenoside Rb1 protects against 6-hydroxydopamine-induced oxidative stress by increasing heme oxygenase-1 expression through an estrogen receptor-related PI3K\/Akt\/Nrf2-dependent pathway in human dopaminergic cells. Toxicol Appl Pharmacol 242:18\u201328","journal-title":"Toxicol Appl Pharmacol"},{"key":"891_CR19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1196\/annals.1427.036","volume":"1147","author":"JA Johnson","year":"2008","unstructured":"Johnson JA, Johnson DA, Kraft AD, Calkins MJ, Jakel RJ, Vargas MR, Chen PC (2008) The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration. Ann N Y Acad Sci 1147:61\u201369","journal-title":"Ann N Y Acad Sci"},{"key":"891_CR20","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.3390\/ijms15033596","volume":"15","author":"C Katnik","year":"2014","unstructured":"Katnik C, Cuevas J (2014) Non-specific inhibition of ischemia- and acidosis-induced intracellular calcium elevations and membrane currents by \u03b1-phenyl-N-tert-butylnitrone, butylated hydroxytoluene and trolox. Int J Mol Sci 15:3596\u20133611","journal-title":"Int J Mol Sci"},{"key":"891_CR21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5607\/en.2015.24.4.325","volume":"24","author":"GH Kim","year":"2015","unstructured":"Kim GH, Kim JE, Rhie SJ, Yoon S (2015) The role of oxidative stress in neurodegenerative diseases. Exp Neurobiol 24:325\u2013340","journal-title":"Exp Neurobiol"},{"key":"891_CR22","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2174\/1871527311211080012","volume":"11","author":"H Kumar","year":"2012","unstructured":"Kumar H, Koppula S, Kim IS, Vasant More S, Kim BW, Choi DK (2012) Nuclear factor erythroid 2-related factor 2 signaling in Parkinson disease: a promising multi therapeutic target against oxidative stress, neuroinflammation and cell death. CNS Neurol Disord Drug Targets 11:1015\u20131029","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"891_CR23","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s12640-015-9550-z","volume":"28","author":"JA Lee","year":"2015","unstructured":"Lee JA, Son HJ, Park KD, Han SH, Shin N, Kim JH, Kim HR, Kim DJ, Hwang O (2015) A novel compound ITC-3 activates the Nrf2 signaling and provides neuroprotection in Parkinson\u2019s disease models. Neurotox Res 28:332\u2013345","journal-title":"Neurotox Res"},{"key":"891_CR24","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00228-015-1919-7","volume":"71","author":"U Lertxundi","year":"2015","unstructured":"Lertxundi U, Isla A, Solinis MA, Domingo-Echaburu S, Hernandez R, Peral-Aguirregoitia J, Medrano J (2015) Anticholinergic burden in Parkinson\u2019s disease inpatients. Eur J Clin Pharmacol 71:1271\u20131277","journal-title":"Eur J Clin Pharmacol"},{"key":"891_CR25","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nature05292","volume":"443","author":"MT Lin","year":"2006","unstructured":"Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787\u2013795","journal-title":"Nature"},{"key":"891_CR26","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1073\/pnas.96.10.5774","volume":"96","author":"AS Mandir","year":"1999","unstructured":"Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-Rosenthal CM, Smulson ME, Hoffman BE, Guastella DB, Dawson VL, Dawson TM (1999) Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci U S A 96:5774\u20135779","journal-title":"Proc Natl Acad Sci U S A"},{"key":"891_CR27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0304-3940(03)00211-8","volume":"341","author":"W Maruyama","year":"2003","unstructured":"Maruyama W, Weinstock M, Youdim MB, Nagai M, Naoi M (2003) Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett 341:233\u2013236","journal-title":"Neurosci Lett"},{"key":"891_CR28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd3430","volume":"10","author":"WG Meissner","year":"2011","unstructured":"Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E (2011) Priorities in Parkinson\u02bcs disease research. Nat Rev Drug Discov 10:377\u2013393","journal-title":"Nat Rev Drug Discov"},{"key":"891_CR29","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bbrc.2005.11.095","volume":"339","author":"K Nakaso","year":"2006","unstructured":"Nakaso K, Nakamura C, Sato H, Imamura K, Takeshima T, Nakashima K (2006) Novel cytoprotective mechanism of anti-parkinsonian drug deprenyl: PI3K and Nrf2-derived induction of antioxidative proteins. Biochem Biophys Res Commun 339:915\u2013922","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl 1","key":"891_CR30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/jnc.13750","volume":"139","author":"W Oertel","year":"2016","unstructured":"Oertel W, Schulz JB (2016) Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J Neurochem 139(Suppl 1):325\u2013337","journal-title":"J Neurochem"},{"key":"891_CR31","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/jnnp-2014-308764","volume":"86","author":"G Pagano","year":"2015","unstructured":"Pagano G, Rengo G, Pasqualetti G, Femminella GD, Monzani F, Ferrara N, Tagliati M (2015) Cholinesterase inhibitors for Parkinson\u02bcs disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 86:767\u2013773","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"891_CR32","first-page":"458","volume":"27","author":"G Ransmayr","year":"2015","unstructured":"Ransmayr G (2015) Cognitive impairment in Parkinson\u02bcs disease. Psychiatr Danub 27:458\u2013461","journal-title":"Psychiatr Danub"},{"key":"891_CR33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s12031-013-0074-9","volume":"51","author":"KR Rekha","year":"2013","unstructured":"Rekha KR, Selvakumar GP, Sethupathy S, Santha K, Sivakamasundari RI (2013) Geraniol ameliorates the motor behavior and neurotrophic factors inadequacy in MPTP-induced mice model of Parkinson\u2019s disease. J Mol Neurosci 51:851\u2013862","journal-title":"J Mol Neurosci"},{"key":"891_CR34","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(14)61010-2","volume":"384","author":"AH Schapira","year":"2014","unstructured":"Schapira AH, Olanow CW, Greenamyre JT, Bezard E (2014) Slowing of neurodegeneration in Parkinson\u02bcs disease and Huntington\u02bcs disease: future therapeutic perspectives. Lancet 384:545\u2013555","journal-title":"Lancet"},{"key":"891_CR35","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0091-3057(03)00129-1","volume":"75","author":"MJ Schwarz","year":"2003","unstructured":"Schwarz MJ, Houghton PJ, Rose S, Jenner P, Lees AD (2003) Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism. Pharmacol Biochem Behav 75:627\u2013633","journal-title":"Pharmacol Biochem Behav"},{"key":"891_CR36","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1046\/j.1471-4159.2003.01686.x","volume":"85","author":"T Shang","year":"2003","unstructured":"Shang T, Uihlein AV, Van Asten J, Kalyanaraman B, Hillard CJ (2003) 1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3. J Neurochem 85:358\u2013367","journal-title":"J Neurochem"},{"key":"891_CR37","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1016\/j.bmc.2012.04.016","volume":"20","author":"Y Sun","year":"2012","unstructured":"Sun Y, Zhang G, Zhang Z, Yu P, Zhong H, Du J, Wang Y (2012) Novel multi-functional nitrones for treatment of ischemic stroke. Bioorg Med Chem 20:3939\u20133945","journal-title":"Bioorg Med Chem"},{"key":"891_CR38","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.amjopharm.2010.08.001","volume":"8","author":"ML Tarrants","year":"2010","unstructured":"Tarrants ML, Denari\u00e9 MF, Castelli-Haley J, Millard J, Zhang D (2010) Drug therapies for Parkinson\u02bcs disease: a database analysis of patient compliance and persistence. Am J Geriatr Pharmacother 8:374\u2013383","journal-title":"Am J Geriatr Pharmacother"},{"key":"891_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128030","volume":"10","author":"M Todorovic","year":"2015","unstructured":"Todorovic M, Newman JR, Shan J, Bentley S, Wood SA, Silburn PA, Mellick GD (2015) Comprehensive assessment of genetic sequence variants in the antioxidant \u2018master regulator\u2019 Nrf2 in idiopathic Parkinson\u2019s disease. PLoS One 10:e0128030. doi: 10.1371\/journal.pone.0128030","journal-title":"PLoS One"},{"key":"891_CR40","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1755-5949.2010.00166.x","volume":"17","author":"T Laar van","year":"2011","unstructured":"van Laar T, De Deyn PP, Aarsland D, Barone P, Galvin JE (2011) Effects of cholinesterase inhibitors in Parkinson\u02bcs disease dementia: a review of clinical data. CNS Neurosci Ther 17:428\u2013441","journal-title":"CNS Neurosci Ther"},{"key":"891_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2016.00327","author":"R Vianello","year":"2016","unstructured":"Vianello R, Domene C, Mavri J (2016) The use of multiscale molecular simulations in understanding a relationship between the structure and function of biological systems of the brain: the application to monoamine oxidase enzymes. Front Neurosci. doi: 10.3389\/fnins.2016.00327","journal-title":"Front Neurosci"},{"key":"891_CR42","doi-asserted-by":"publisher","first-page":"648740","DOI":"10.1155\/2014\/648740","volume":"2014","author":"A Xie","year":"2014","unstructured":"Xie A, Gao J, Xu L, Meng D (2014) Shared mechanisms of neurodegeneration in Alzheimer\u02bcs disease and Parkinson's disease. Biomed Res Int 2014:648740. doi: 10.1155\/2014\/648740","journal-title":"Biomed Res Int"},{"key":"891_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5607\/en.2013.22.1.1","volume":"22","author":"MB Youdim","year":"2013","unstructured":"Youdim MB (2013) Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and M30 derived from rasagiline. Exp Neurobiol 22:1\u201310","journal-title":"Exp Neurobiol"},{"key":"891_CR44","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1212\/WNL.63.7_suppl_2.S32","volume":"63","author":"MB Youdim","year":"2004","unstructured":"Youdim MB, Riederer PF (2004) A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson\u2019s disease. Neurology 63:S32\u2013S35","journal-title":"Neurology"},{"key":"891_CR45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1353-8020(01)00011-6","volume":"8","author":"MB Youdim","year":"2002","unstructured":"Youdim MB, Tipton KF (2002) Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson\u02bcs disease. Parkinsonism Relat Disord 8:247\u2013253","journal-title":"Parkinsonism Relat Disord"},{"key":"891_CR46","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1023\/A:1015131516649","volume":"21","author":"MB Youdim","year":"2001","unstructured":"Youdim MB, Weinstock M (2001) Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate]. Cell Mol Neurobiol 21:555\u2013573","journal-title":"Cell Mol Neurobiol"},{"key":"891_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2016.11.054","author":"W Zeng","year":"2016","unstructured":"Zeng W, Zhang W, Lu F, Gao L, Gao G (2016) Resveratrol attenuates MPP+-induced mitochondrial dysfunction and cell apoptosis via AKT\/GSK-3\u03b2 pathway in SN4741 cells. Neurosci Lett. doi: 10.1016\/j.neulet.2016.11.054","journal-title":"Neurosci Lett"},{"key":"891_CR48","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.pbb.2014.03.028","volume":"122","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Lai D, Wang L, Yu P, Zhu L, Guo B, Xu L, Zhou L, Sun Y, Lee SM, Wang Y (2014) Neuroprotective effects of the andrographolide analogue AL-1 in the MPP+\/MPTP-induced Parkinson\u02bcs disease model in vitro and in mice. Pharmacol Biochem Behav 122:191\u2013202","journal-title":"Pharmacol Biochem Behav"},{"key":"891_CR49","doi-asserted-by":"crossref","first-page":"8171","DOI":"10.1021\/jf301511m","volume":"60","author":"ZJ Zhang","year":"2012","unstructured":"Zhang ZJ, Cui W, Li GH, Yuan S, Xu DP, Hoi MPM, Lin ZX, Dou J, Han YF, Lee SMY (2012) Baicalein protects against 6-OHDA-induced neurotoxicity through activation of Keap1\/Nrf2\/HO-1 and involving PKC\u03b1 and PI3K\/AKT signaling pathways. J Agric Food Chem 60:8171\u20138182","journal-title":"J Agric Food Chem"}],"container-title":["Journal of Molecular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-017-0891-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12031-017-0891-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-017-0891-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T14:42:07Z","timestamp":1589726527000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12031-017-0891-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,31]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1007\/s12031-017-0891-3","relation":{},"ISSN":["0895-8696","1559-1166"],"issn-type":[{"value":"0895-8696","type":"print"},{"value":"1559-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,31]]}}}